Therapeutic synthetic gene networks

Current Opinion in Biotechnology

Volumn 23, Issue 5, 2012, Pages 703-711

  Karlsson, Maria ^a,b   Weber, Wilfried ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL INSEMINATION; BIOMEDICAL APPLICATIONS; BIOSENSING DEVICES; CELL FATES; CLOSED-LOOP; GENE NETWORKS; INTERDISCIPLINARY WORK; LOGICAL FUNCTIONS; METABOLIC DISORDERS; OPEN LOOPS; PERSONALIZED MEDICINES; RECENT PROGRESS; STIMULI-RESPONSIVE; SYNTHETIC BIOLOGY; SYNTHETIC CONTROL; SYNTHETIC GENE NETWORK; SYNTHETIC GENES;

BIOLOGY; MEDICAL APPLICATIONS; NETWORKS (CIRCUITS);

GENE THERAPY;

APTAMER; CELLULOSE SULFATE; GLUCAGON LIKE PEPTIDE 1; INTERLEUKIN 4; MELANOPSIN; TETRACYCLINE; URATE OXIDASE; URIC ACID; VIRUS VECTOR; ZINC FINGER NUCLEASE;

ARTIFICIAL INSEMINATION; BIOSENSOR; CANCER THERAPY; CONTROLLED DRUG RELEASE; GENE EXPRESSION REGULATION; GENE EXPRESSION SYSTEM; GENE NETWORK; GENE SWITCHING; GENE THERAPY; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; HYDROGEL; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SYNTHETIC BIOLOGY; TUMOR LYSIS SYNDROME;

ANIMALS; GENE REGULATORY NETWORKS; GENES, SYNTHETIC; GENETIC THERAPY; GLUCOSE; GOUT; HUMANS; INSEMINATION, ARTIFICIAL; LOGIC; METABOLIC DISEASES; NEOPLASMS; SYNTHETIC BIOLOGY;

EID: 84867206834     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2012.01.003     Document Type: Review

References (54)

1. Weber W., Fussenegger M. Emerging biomedical applications of synthetic biology. Nat Rev Genet 2012, 13:21-35.
2. Karlsson M., Weber W., Fussenegger M. De novo design and construction of an inducible gene expression system in mammalian cells. Methods Enzymol 2011, 497:239-253.
3. Weber W., Fussenegger M. Molecular diversity-the toolbox for synthetic gene switches and networks. Curr Opin Chem Biol 2011, 15:414-420.
4. Kramer B.P., Viretta A.U., Daoud-El-Baba M., Aubel D., Weber W., Fussenegger M. An engineered epigenetic transgene switch in mammalian cells. Nat Biotechnol 2004, 22:867-870.
5. Gardner T.S., Cantor C.R., Collins J.J. Construction of a genetic toggle switch in Escherichia coli. Nature 2000, 403:339-342.
6. Burrill D.R., Silver P.A. Making cellular memories. Cell 2010, 140:13-18.
7. Yao G., Tan C., West M., Nevins J.R., You L. Origin of bistability underlying mammalian cell cycle entry. Mol Syst Biol 2011, 7:485.
8. Ozbudak E.M., Thattai M., Lim H.N., Shraiman B.I., Van Oudenaarden A. Multistability in the lactose utilization network of Escherichia coli. Nature 2004, 427:737-740.
9. Atkinson M.R., Savageau M.A., Myers J.T., Ninfa A.J. Development of genetic circuitry exhibiting toggle switch or oscillatory behavior in Escherichia coli. Cell 2003, 113:597-607.
10. Kramer B.P., Fussenegger M. Hysteresis in a synthetic mammalian gene network. Proc Natl Acad Sci U S A 2005, 102:9517-9522.
11. Tigges M., Marquez-Lago T.T., Stelling J., Fussenegger M. A tunable synthetic mammalian oscillator. Nature 2009, 457:309-312.
12. Tigges M., Denervaud N., Greber D., Stelling J., Fussenegger M. A synthetic low-frequency mammalian oscillator. Nucleic Acids Res 2010, 38:2702-2711.
13. Aubel D., Fussenegger M. Mammalian synthetic biology-from tools to therapies. Bioessays 2010, 32:332-345.
14. Toettcher J.E., Mock C., Batchelor E., Loewer A., Lahav G. A synthetic-natural hybrid oscillator in human cells. Proc Natl Acad Sci U S A 2010, 107:17047-17052.
15. Swinburne I.A., Miguez D.G., Landgraf D., Silver P.A. Intron length increases oscillatory periods of gene expression in animal cells. Genes Dev 2008, 22:2342-2346.
16. Stricker J., Cookson S., Bennett M.R., Mather W.H., Tsimring L.S., Hasty J. A fast, robust and tunable synthetic gene oscillator. Nature 2008, 456:516-519.
17. Danino T., Mondragon-Palomino O., Tsimring L., Hasty J. A synchronized quorum of genetic clocks. Nature 2010, 463:326-330.
18. Basu S., Gerchman Y., Collins C.H., Arnold F.H., Weiss R. A synthetic multicellular system for programmed pattern formation. Nature 2005, 434:1130-1134.
19. Weber W., Stelling J., Rimann M., Keller B., Daoud-El Baba M., Weber C.C., Aubel D., Fussenegger M. A synthetic time-delay circuit in mammalian cells and mice. Proc Natl Acad Sci U S A 2007, 104:2643-2648.
20. Jakobus K., Wend S., Weber W. Synthetic mammalian gene networks as a blueprint for the design of interactive biohybrid materials. Chem Soc Rev 2011, 41:1000-1018.
21. Christen E.H., Karlsson M., Kampf M.M., Schoenmakers R., Gubeli R.J., Wischhusen H.M., Friedrich C., Fussenegger M., Weber W. Conditional DNA-protein interactions confer stimulus-sensing properties to biohybrid materials. Adv Funct Mater 2011, 21:2861-2867.
22. Kampf M.M., Christen E.H., Ehrbar M., Daoud-El Baba M., Charpin-El Hamri G., Fussenegger M., Weber W. A gene therapy technology-based biomaterial for the trigger-inducible release of biopharmaceuticals in mice. Adv Funct Mater 2010, 20:2534-2538.
23. Ehrbar M., Schoenmakers R., Christen E.H., Fussenegger M., Weber W. Drug-sensing hydrogels for the inducible release of biopharmaceuticals. Nat Mater 2008, 7:800-804.
24. Kemmer C., Fluri D.A., Witschi U., Passeraub A., Gutzwiller A., Fussenegger M. A designer network coordinating bovine artificial insemination by ovulation-triggered release of implanted sperms. J Control Release 2011, 150:23-29.
25. Yazawa M., Sadaghiani A.M., Hsueh B., Dolmetsch R.E. Induction of protein-protein interactions in live cells using light. Nat Biotechnol 2009, 27:941-945.
26. Ye H., Daoud-El Baba M., Peng R.W., Fussenegger M. A synthetic optogenetic transcription device enhances blood-glucose homeostasis in mice. Science 2011, 332:1565-1568.
27. Cairo M.S., Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004, 127:3-11.
28. Terkeltaub R.A. Clinical practice. Gout. N Engl J Med 2003, 349:1647-1655.
29. Kemmer C., Gitzinger M., Daoud-El Baba M., Djonov V., Stelling J., Fussenegger M. Self-sufficient control of urate homeostasis in mice by a synthetic circuit. Nat Biotechnol 2010, 28:355-360.
30. Wilkinson S.P., Grove A. HucR, a novel uric acid-responsive member of the MarR family of transcriptional regulators from Deinococcus radiodurans. J Biol Chem 2004, 279:51442-51450.
31. Enomoto A., Kimura H., Chairoungdua A., Shigeta Y., Jutabha P., Cha S.H., Hosoyamada M., Takeda M., Sekine T., Igarashi T., et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002, 417:447-452.
32. Nissim L., Bar-Ziv R.H. A tunable dual-promoter integrator for targeting of cancer cells. Mol Syst Biol 2010, 6:444.
33. Xie Z., Wroblewska L., Prochazka L., Weiss R., Benenson Y. Multi-input RNAi-based logic circuit for identification of specific cancer cells. Science 2011, 333:1307-1311.
34. Culler S.J., Hoff K.G., Smolke C.D. Reprogramming cellular behavior with RNA controllers responsive to endogenous proteins. Science 2010, 330:1251-1255.
35. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 2011, 12:301-315.
36. Gabriel R., Eckenberg R., Paruzynski A., Bartholomae C.C., Nowrouzi A., Arens A., Howe S.J., Recchia A., Cattoglio C., Wang W., et al. Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med 2009, 15:1431-1436.
37. Fischer A., Hacein-Bey-Abina S., Cavazzana-Calvo M. 20 years of gene therapy for SCID. Nat Immunol 2010, 11:457-460.
38. Hacein-Bey-Abina S., Hauer J., Lim A., Picard C., Wang G.P., Berry C.C., Martinache C., Rieux-Laucat F., Latour S., Belohradsky B.H., et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010, 363:355-364.
39. Aiuti A., Cattaneo F., Galimberti S., Benninghoff U., Cassani B., Callegaro L., Scaramuzza S., Andolfi G., Mirolo M., Brigida I., et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009, 360:447-458.
40. Hacein-Bey-Abina S., Garrigue A., Wang G.P., Soulier J., Lim A., Morillon E., Clappier E., Caccavelli L., Delabesse E., Beldjord K., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008, 118:3132-3142.
41. Howe S.J., Mansour M.R., Schwarzwaelder K., Bartholomae C., Hubank M., Kempski H., Brugman M.H., Pike-Overzet K., Chatters S.J., de Ridder D., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008, 118:3143-3150.
42. Brown B.D., Venneri M.A., Zingale A., Sergi Sergi L., Naldini L. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 2006, 12:585-591.
43. Gentner B., Visigalli I., Hiramatsu H., Lechman E., Ungari S., Giustacchini A., Schira G., Amendola M., Quattrini A., Martino S., et al. Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy. Sci Transl Med 2010, 2:58ra84.
44. Brown B.D., Gentner B., Cantore A., Colleoni S., Amendola M., Zingale A., Baccarini A., Lazzari G., Galli C., Naldini L. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 2007, 25:1457-1467.
45. Carroll D. Progress and prospects: zinc-finger nucleases as gene therapy agents. Gene Ther 2008, 15:1463-1468.
46. Sander J.D., Dahlborg E.J., Goodwin M.J., Cade L., Zhang F., Cifuentes D., Curtin S.J., Blackburn J.S., Thibodeau-Beganny S., Qi Y., et al. Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). Nat Methods 2011, 8:67-69.
47. Urnov F.D., Rebar E.J., Holmes M.C., Zhang H.S., Gregory P.D. Genome editing with engineered zinc finger nucleases. Nat Rev Genet 2010, 11:636-646.
48. Silva G., Poirot L., Galetto R., Smith J., Montoya G., Duchateau P., Paques F. Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Curr Gene Ther 2011, 11:11-27.
49. Christian M., Cermak T., Doyle E.L., Schmidt C., Zhang F., Hummel A., Bogdanove A.J., Voytas D.F. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 2010, 186:757-761.
50. Miller J.C., Tan S., Qiao G., Barlow K.A., Wang J., Xia D.F., Meng X., Paschon D.E., Leung E., Hinkley S.J., et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 2011, 29:143-148.
51. Perez E.E., Wang J., Miller J.C., Jouvenot Y., Kim K.A., Liu O., Wang N., Lee G., Bartsevich V.V., Lee Y.L., et al. Establishment of HIV-1 resistance in CD4+ T-cells by genome editing using zinc-finger nucleases. Nat Biotechnol 2008, 26:808-816.
52. Holt N., Wang J., Kim K., Friedman G., Wang X., Taupin V., Crooks G.M., Kohn D.B., Gregory P.D., Holmes M.C., et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010, 28:839-847.
53. Rollins C.T., Rivera V.M., Woolfson D.N., Keenan T., Hatada M., Adams S.E., Andrade L.J., Yaeger D., van Schravendijk M.R., Holt D.A., et al. A ligand-reversible dimerization system for controlling protein-protein interactions. Proc Natl Acad Sci U S A 2000, 97:7096-7101.
54. Rivera V.M., Wang X., Wardwell S., Courage N.L., Volchuk A., Keenan T., Holt D.A., Gilman M., Orci L., Cerasoli F., et al. Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum. Science 2000, 287:826-830.